Andrén Aronsson, C., Lee, H-S., Hård Af Segerstad , E., Uusitalo, U., Yang, J., Koletzko, S., Liu, E., Kurppa, K., Bingley, P., Toppari, J., Ziegler, A-G., She, J-X., Hagopian, W., Rewers, M., Akolkar, B., Krischer, J., Virtanen, S. M., Norris, J. M., & Agardh, D. (2019). Association of gluten intake during the first 5 years with incidence of celiac disease autoimmunity and celiac disease among children at increased risk. *JAMA - Journal of the American Medical Association*, *322*(6), 514-523. https://doi.org/10.1001/jama.2019.10329

Peer reviewed version

Link to published version (if available):
10.1001/jama.2019.10329

Association of gluten intake in the first 5 years with incidence of celiac disease autoimmunity and celiac disease among children at increased risk

Carin Andrén Aronsson[1] Ph.D., Hye-Seung Lee[2] Ph.D., Elin M Hård af Segerstad[1] M.Sc., Ulla Uusitalo[2] Ph.D., Jimin Yang[2] Ph.D, Sibylle Koletzko[3] M.D., Ph.D., Edwin Liu[4] M.D., Ph.D., Kalle Kurppa[5] M.D, Ph.D., Polly J Bingley[6] M.D., Jorma Toppari[7-8] M.D.,Ph.D., Anette-G Ziegler[9] M.D., Jin-Xiong She[10], Ph.D., William A Hagopian[11] M.D., Ph.D., Marian Rewers[12] M.D., Ph.D., Beena Akolkar[13] Ph.D., Jeffrey P Krischer[2] Ph.D., Suvi M Virtanen[14-16] M.D., Ph.D., Jill M Norris[17] MPH, Ph.D., Daniel Agardh[1] M.D., Ph.D., for the TEDDY Study Group

Affiliations:

[1] Department of Clinical Sciences, Lund University, Malmö, Sweden.

[2] Health Informatics Institute, Department of Pediatrics, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.

[3] Dr. von Hauner Children´s Hospital, Ludwig Maximilians University, Munich, Germany

[4] Digestive Health Institute, University of Colorado Denver, Children's Hospital Colorado, Denver, CO, USA.

[5] Tampere Centre for Child Health Research, University of Tampere and Tampere University Hospital, Tampere, Finland

[6] School of Clinical Sciences, University of Bristol, Bristol, United Kingdom

[7] Research Centre for Integrative Physiology and Pharmacology, Institute of Biomedicine, University of Turku, Turku, Finland

[8] Department of Pediatrics, Turku University Hospital, Turku, Finland

[9] Institute of Diabetes Research, Helmholtz Zentrum München, and Klinikum rechts der Isar, Technische Universität München, and Forschergruppe Diabetes e.V., Neuherberg, Germany

[10] Center for Biotechnology and Genomic Medicine, Augusta University, Augusta, GA, USA

[11] Pacific Northwest Diabetes Research Institute, Seattle, WA, USA

[12] Barbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine, Aurora, CO, USA

[13] National Institute of Diabetes & Digestive & Kidney Diseases, Bethesda MD, USA

[14] National Institute for Health and Welfare, Department of Public Health Solutions, Helsinki, Finland.

[15] Faculty of Social Sciences/Health Sciences, University of Tampere, Tampere, Finland.
[16] Research center for Child Health, Tampere University and University Hospital and the Science center of Pirkanmaa Hospital District, Tampere, Finland.
[17] Department of Epidemiology, University of Colorado Denver, Colorado School of Public Health, Aurora, CO, USA.

Corresponding author:
Daniel Agardh, M.D., Ph.D
Department of Clinical Sciences, Diabetes and Celiac Disease unit, Lund University
Clinical Research Centre, Jan Waldenströms gata 35, 20502 Malmö, Sweden
Phone: +46 40 391113
E-mail: daniel.agardh@med.lu.se

Word count of the manuscript: 3367

Date of revision: May 21, 2019

Key Points

Question: Is the amount of gluten intake in the first 5 years associated with the risk of celiac disease autoimmunity and celiac disease in at-risk children?

Findings: In this multinational prospective birth cohort consisting of 6,605 genetically predisposed children, higher gluten intake was associated with a statistically significant increase of celiac disease autoimmunity (HR 1.30, 95% CI 1.22-1.38) and celiac disease (HR 1.50, 95% CI 1.35-1.66), for every gram increase of gluten intake per day.

Meaning: Increased intake of gluten during the first 5 years of life was an independent risk factor of celiac disease autoimmunity and celiac disease in genetically predisposed children.

Abstract

Importance: High gluten intake during childhood may confer risk of celiac disease.

Objectives: To investigate if the amount of gluten intake is associated with celiac disease autoimmunity and celiac disease in genetically at risk children.

Design, Setting, and Participants: The Environmental Determinants of Diabetes in the Young (TEDDY), a prospective observational birth cohort designed to identify environmental triggers of type 1 diabetes and celiac disease. Participants were followed at six clinical centers in Finland, Germany, Sweden and the US. Between 2004 and 2010, 8,676 newborns carrying HLA-genotypes associated with type 1 diabetes and celiac disease, were enrolled into a longitudinal observational study. In 6,757 children, screening for celiac disease with tissue transglutaminase (tTG) autoantibodies was performed annually from age 2 years. Data on gluten intake were available in 6,605 (98%) children.

Exposure: Gluten intake was estimated from 3-day food records collected at 6, 9, and 12 months and biannually thereafter until age 5 years.

Main Outcomes: The primary endpoint was celiac disease autoimmunity, defined as positive tTG autoantibodies in two consecutive serum samples. The secondary endpoint was celiac disease confirmed by intestinal biopsy or persistently high tTG autoantibody levels.

Results: Of the 6,605 children (49% females, median follow-up 9.0 years [interquartile range 8.0 to 10.0 years]), 1,216 (18%) developed celiac disease autoimmunity and 447 (7%) developed celiac disease by September 30, 2017. The incidence for both endpoints peaked at age 2 to 3 years. Daily gluten intake was associated with higher risk of celiac disease autoimmunity (HR 1.30, 95% CI 1.22-1.38) and celiac disease (HR 1.50, 95% CI 1.35-1.66) for every 1-gram/day increase. The absolute risk increases corresponding to HR were 6.1% for celiac disease autoimmunity and 7.2% for celiac disease, respectively.

Conclusions and Relevance: Higher gluten intake in the first 5 years was associated with

increased risk of celiac disease autoimmunity and celiac disease among genetically predisposed children.

Introduction

Gluten is a food antigen found in wheat, rye and barley. It has a high content of proteins rich in gliadin peptides, which are resistant to complete digestion by gastrointestinal enzymes, and may cause an inflammatory response leading to celiac disease in genetically predisposed individuals[1]. Celiac disease is an autoimmune enteropathy affecting approximately 1% of the western population and attributable to both genetic and environmental factors[2]. While gluten consumption and certain human leukocyte antigen (HLA) genes are key factors for celiac disease development, not all individuals with a predisposing genetic background develop lifelong intolerance to gluten[3], and the risk is likely to be modified by the timing or quantities of gluten consumed as well as other potential pathophysiologic factors[4,5].

Celiac disease commonly presents early in childhood[6], highlighting the importance of studying early life events for identifying triggers of the disease[7]. It was initially reported that early or late introduction of gluten to infants increased the risk of celiac disease[8,9]. The timing of infant gluten exposure has not been consistently associated with celiac disease risk[10,11], and this has led to changing recommendations for infant feeding[12]. Importantly, it remains unclear whether the amount of gluten consumed triggers celiac disease[11,13-15.]

Gluten intake during the first 5 years of life was assessed from genetically at-risk children followed in the multinational prospective birth cohort the Environmental Determinants of Diabetes in the Young (TEDDY) study. The aim was to investigate whether the amount of gluten in the diet was associated with development of celiac disease autoimmunity and celiac disease, to allow better understanding of the pathogenesis and to inform feeding recommendations to minimize disease burden.

Methods

Study population

This prospective cohort study follows children from birth up to 15 years of age at clinical research centers in Colorado, Georgia, Florida, and Washington state in the U.S., as well as Finland, Germany, and Sweden[16]. The final date of follow-up for the present study was September 30, 2017.

The primary goal was to identify genetic and environmental factors associated with increased risk of type 1 diabetes, celiac disease, or both. Newborn infants were screened for HLA genotypes associated with type 1 diabetes and celiac disease[17]. Distribution of the HLA-genotypes in the study is shown in **Table 1.** For all study participants separate written informed consents for genetic screening and participation in the prospective follow-up beginning at birth were obtained from a parent or primary caretaker. Local institutional or regional ethics review boards in all participating countries approved the study. Full details of study design, eligibility and methods have been published previously[16,18-20].

Dietary assessment

Gluten intake was estimated from 3-day food records collected at ages 6, 9, and 12 months and biannually (i.e. at 18, 24, 30, 36 months) thereafter until 5 years of age. Parents were asked to keep a food record documenting all foods and drinks consumed by the child over the 3-day periods (2 weekdays and 1 weekend day) before the scheduled clinic visit. Normal food habits were encouraged during the time of food record collection. Portion sizes were estimated using household measurements, food models, pictures, drawings and shapes of foods as references. A specific booklet was developed and used in all countries to facilitate estimation of food portion sizes. The dietary assessment method used in the study has been described in detail elsewhere[15,21].

Dietary intake was analyzed using the food composition databases from each participating country. For analyses at the food group level, a harmonized food grouping system was developed with comparable food groups and quantification of food intakes between the databases used in individual countries[22]. Composite foods and recipes were broken down to ingredients. Mean intake (g/day) was calculated from total intake of gluten-containing flours (wheat, rye, and barley) reported in the 3-day recording period. Vegetable protein content (using country-specific values) was obtained from the daily intake of gluten-containing flours and converted to amount of gluten using a conversion factor of 0.8 (gluten content in wheat protein)[23]. The converted amount was analyzed as absolute gluten intake (g/day).

Measurement of tissue transglutaminase (tTG) autoantibodies

Testing for serum tTG autoantibodies started from the 24 months clinic visit and continued yearly thereafter. Radiobinding assays were used to measure tTG autoantibody levels in two laboratories as previously described[19]. Briefly, samples from US centers were screened for IgA-tTG autoantibodies at the Barbara Davis Center for Childhood Diabetes, University of Colorado (Denver laboratory)[24]. Samples from European centers were tested at the University of Bristol, UK, (Bristol laboratory), using an assay that detected both IgA and IgG autoantibodies against tTG[25]. To harmonize results, all samples with tTG autoantibody index >0.01 in the Denver laboratory were sent for quantification of tTG autoantibodies in the Bristol laboratory, the reference laboratory for the study[19]. Results were expressed in arbitrary units derived from a standard curve consisting of dilutions of serum taken from a patient with celiac disease. If a sample tested positive from the Bristol laboratory (≥1.3 units)[25], the child's earlier blood samples were retrospectively analyzed in the Bristol laboratory to determine the age at which tTG autoantibodies first became detectable. Persistence of tTG autoantibodies

was confirmed by finding positive results in two consecutive samples at least 3 months apart[26].

Outcomes

The primary outcome was celiac disease autoimmunity, defined as positive tTG autoantibodies measured in the Bristol laboratory in two consecutive samples. Children meeting the criteria for persistence of tTG autoantibodies were referred to a gastroenterologist at the clinical discretion of their usual physician. The decision whether to perform a biopsy was not determined by the TEDDY study protocol. The secondary endpoint was celiac disease, which was defined as an intestinal biopsy showing a Marsh score ≥2 or, if biopsy was not performed, non-biopsy proven celiac disease was defined by the average of two samples ≥100 units[26].

Statistical analyses

Time to event was defined as the age of the first positive tTG autoantibody sample for children who later fulfilled the criteria for both celiac disease autoimmunity and celiac disease. The right censored time for celiac disease autoimmunity was the age at the last negative tTG autoantibody sample and for celiac disease was the age at the last clinic visit at which celiac disease had not been diagnosed. In order to control for differences in age or body size, we analyzed energy and age adjusted intake using the residual method[27], as well as intake per 10 kg bodyweight at a given age, in addition to absolute daily intake.

To address concerns regarding missing data and variability in dietary data, joint modeling was selected as the pre-specified analysis, chosen to assess the association between gluten intake over time and the risk of celiac disease autoimmunity and celiac disease[28,29]. Joint modeling assesses the association by fitting an individual trajectory for the intake over time. Based on

the patterns seen in **eFigure 1** and **eFigure 2**, a linear trajectory was assumed for the longitudinal model and the incidence peak in the beginning was considered for the baseline hazard estimation assuming piecewise constant. Seven intervals without weighting were applied per the best model fit based on ΔAIC[30]. The longitudinal model was adjusted for energy intake (kcal/day) at the same time, and the time to event model was adjusted for HLA-genotype, sex, country of residence and family history (mother, father, or sibling) of celiac disease. SAS macro JMFit was used for the analyses[31]. From the log-hazard model fitted by joint modeling, absolute risk by 3 years old was estimated as the cumulative hazard, in relation to the average daily gluten intake at 2 years of age. The hazard ratios and absolute risk increases were assessed at 1 unit increase of gluten intake, conditioned on energy intake (kcal/day) at the same time, HLA-genotype, sex, country of residence and family history of celiac disease.

In addition, two Cox regression analyses including the most recent intake prior to the event and energy intake at the same time as time dependent covariates were performed as sensitivity analyses: 1) all children, and 2) children with gluten intake available within 1 year prior to each risk-set, to control for various lag times between gluten exposure and the event.

As a post-hoc analysis, we examined the effects of age-specific gluten intake. The association with subsequent incidence of celiac disease autoimmunity and celiac disease was assessed using Cox regression, focusing on absolute intake reported at the age of each TEDDY visit. For children whose gluten intake at the specific age was the most recent data prior to the event, the standard Cox regression model assessed the effects of gluten intake reported at the specific age as a time constant covariate. For children who had additional gluten intake data available after the specific age, the most recent gluten intake prior to the event needs to be controlled to assess the effects of the intake reported at the specific age (i.e., the primary

interest). In order to assess the effects of age-specific gluten intake in addition to the effect of current intake, the model considered the most recent intake prior to the event as a time dependent covariate and the intake at the specific age as a time constant covariate.

The proportional hazard assumption was examined using martingale residual analysis with the supremum test. The functional form in the martingale residual plot, as well as change-point analysis based on log-rank test[32], suggested a dichotomization for absolute gluten intake at 2 years of age.

Two-sided p-values are reported. Statistical significance was determined when the p-value was <0.05. All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC).

Results

Between September 2004 and February 2010, 424,788 newborn infants were screened for HLA and 21,589 (5%) HLA-eligible infants were identified, of whom 8,676 (40%) were enrolled in this study before the age of 4 months. The most common reasons for failing to enroll to this 15-year follow-up study were related to protocol characteristics (e.g. blood draw, demanding protocol) or family circumstances (e.g. changing contact information)[33]. At time of analysis, 6,757 children had been screened for tTG autoantibodies, and 6,605 (97.8%) had submitted at least one 3-day food record during the first 5 years of life or prior to detection of tTG autoantibody positivity (**eFigure 3**). Descriptive characteristics of the study population are presented in **Table 1**. Of 6,605 children in the study, 3,233 (49%) were girls. Data on gluten intake were missing or of inadequate quality in 4,465 visits (8%) of the 52,952 visits for which parallel tTG results were available. In total, 204 (3%) subjects completed at only one food record. Among children with celiac disease autoimmunity, 20 (1.6%) subjects completed one food record more than 3 months prior to their seroconversion.

As of September 30, 2017, among the 6,605 children included in the analysis, 1,411 (21%) had tested positive for tTG autoantibodies on at least one occasion. During a median follow up of 9.0 years (range 1.0 – 13.0, interquartile range 8.0 – 10.0) 1,216 (18%) children with celiac disease autoimmunity had seroconverted to positive tTGA autoantibodies at a median age of 3.3 years (range 0.9 - 11.5), and 447 (7%) children fulfilling the criteria for celiac disease had their seroconversion at a median age of 3.0 years (range 0.9 – 11.2). The incidence of seroconversion for both endpoints peaked around 2 to 3 years of age (**eFigure 1**).

Children homozygous for DR3-DQ2 were at the highest risk of celiac disease autoimmunity and celiac disease. Swedish residence, female sex, and family history of celiac disease were also associated with increased risk for both endpoints (**eTable 1**).

Gluten consumption linearly increased with age with some national differences (**eFigure 2, eTable 2**). Higher intake of gluten during the first 5 years of life was associated with increased risk of both celiac disease autoimmunity and celiac disease (**Table 2**). Absolute intake of gluten was associated with higher risk of celiac disease autoimmunity (HR 1.30, 95% CI 1.22 -1.38; p= <0.001) and celiac disease (HR 1.50, 95% CI 1.35 -1.66; p= <0.001) for every per 1-gram/day increase in gluten consumption. Age- and energy adjusted gluten intake was associated with higher risk of celiac disease autoimmunity (HR 1.40, 95% CI 1.30 -1.52; p= <0.001) and celiac disease (HR 1.43, 95% CI 1.23 -1.68; p= <0.001) for every per 1-gram/day increase in gluten consumption. In addition, gluten intake per 10 kg bodyweight was associated with higher risk of celiac disease autoimmunity (HR 1.87, 95% CI 1.66 -2.11; p= <0.001) and celiac disease (HR 2.18, 95% CI 1.75 -2.71; p= <0.001) for every per 1-gram/day/10kg increase in gluten consumption. Sensitivity analysis using Cox regression models supported the statistical significance found from the joint modeling analysis (**Table 2**).

In the country-specific analyses, a higher gluten intake was associated with an increased risk of celiac disease autoimmunity in all countries (**eTable 3**). Absolute gluten intake and age- and energy adjusted intake were associated with increased risk for celiac disease in the U.S. and Sweden.

Finally, the absolute risks by 3 years of age in relation to the average daily gluten intake at 2 years of age were assessed. The absolute risk difference suggests the risk increase if gluten was 1 unit higher than the average daily gluten intake at 2 years of age. The absolute risk increases were 6 to 18% for celiac disease autoimmunity and 3 to 20% celiac disease, respectively (**Table 3**).

Post-hoc analysis

In view of the early peak incidence of seroconversion to later celiac disease autoimmunity and celiac disease, we focused on the intake reported at 2 and 3 years of age, respectively. Gluten intake reported at the 2-year visit was available for 833 children with celiac disease autoimmunity and intake reported at the 3-year visit was available for 526 children with celiac disease autoimmunity. The analysis showed that gluten intake at 2 years of age had an independent effect on the risk of celiac disease autoimmunity and celiac disease, in addition to the current intake during the first 5 years of life (**eTable 4**).

The supremum test showed no indication of violating the proportional hazard assumption, but there was a deviation at >2g gluten intake per day in the martingale residual plot (**eFigure 4**). In addition, the change point analysis showed a significance risk difference between >2 and ≤ 2g/day. Based on these analyses, we dichotomized the gluten intake reported at 2 years as >2 and ≤2 g/day and examined the adjusted HRs with the endpoints (**Table 4**). Children who consumed gluten >2g/day at 2 years of age had a 50% higher risk of celiac disease autoimmunity (HR 1.49, 95% CI 1.16 – 1.91; p= <0.002) and a 75% higher risk of celiac disease (HR 1.75, 95% CI 1.10 – 2.81; p= <0.019), compared with those who consumed ≤2g

gluten per day. When analyzing absolute gluten intake reported at the 2-year visit and risk for developing celiac disease autoimmunity and celiac disease, using a subsequent increase in gluten intake, a linear increase in hazard ratios were seen for higher intakes (**Table 5**).

Discussion

Higher gluten intake in the first 5 years was associated with increased risk of celiac disease autoimmunity and celiac disease among genetically predisposed children.

The incidence of both endpoints peaked around 2 to 3 years of age. In the post-hoc analysis, the association with gluten intake on these risks was significantly increased if the child consumed more than 2 g/day at around 2 years of age, which corresponds to approximately one slice (35 g) of white bread or 1 portion of cooked pasta (150g). Also, hazard ratios increased with subsequent higher gluten intake at the 2 year visit suggesting that higher intakes were associated with higher risk of celiac disease autoimmunity and celiac disease.

These findings are in line with a previous retrospective case-control study of gluten intake in Swedish children born during the mid-1980s, which showed that children subsequently diagnosed with celiac disease had been introduced to larger amounts of gluten-containing foods compared with children who did not develop celiac disease[13].

The hypothesis that gluten given in small amounts at 5 to 6 months of age would protect at-risk children from developing celiac disease was furthermore addressed in a randomized placebo-controlled intervention trial, though with null results[11]. In the same study population, mean daily gluten intake, from 10 months of age when unrestricted gluten consumption was allowed, was not associated with celiac disease up to 3 years of age, except in children carrying the HLA-genotype HLA-DQ2.2/-DQ7[14].

In contrast to the randomized placebo-controlled intervention trial, gluten consumption during the first 2 years of life was previously found associated with increased risk of celiac disease in a subset of Swedish children from the present cohort, and furthermore, children in the upper

tertile of gluten intake were at a 2-fold increased risk of celiac disease, compared with children with lower gluten intake. This nested case-control study on 146 children with biopsy confirmed celiac disease and 436 matched controls indicated that the amount of gluten consumed could be a risk factor for celiac disease[15].

For the current study, food record data from all the participating countries have been harmonized which enabled us to do longitudinal analysis of the full birth cohort. In addition, we have extended the data with gluten intake up to 5 years of age and included another 301 children diagnosed with celiac disease and performed time to event analyses. This extended data set yields credible power to do country-specific analysis for celiac disease autoimmunity and celiac disease, except for the German site, which had only 16 cases with celiac disease. In these country-specific analyses, a higher gluten intake was associated with an increased risk of celiac disease autoimmunity in all countries, whereas absolute gluten intake and age- and energy adjusted intake were only associated with increased risk for celiac disease in the U.S. and Sweden.

Despite similar dietary assessment methods and calculation of gluten intake, discrepancies in results between the studies are likely attributed to study design and population size. In the randomized controlled study, the gluten introduction was overlooked and gluten amounts were fixed[11], which indeed differed from the present observational study consisting of a larger population that reflected the natural variations of gluten intake in real life. Other contributing factors may be differences in exposures to various triggering environmental factors such as gastrointestinal infections or rotavirus vaccination status[5], which partly could explain why Swedish children are more prone to develop celiac disease as compared to children from other countries.

A major strength of this study as compared to the aforementioned the randomized controlled study [11], is its prospective study design, enrolling a large cohort of children with the same

genetic risk, from four countries with different infant feeding habits and following the same study protocol. Another strength is the dietary assessment method that allowed repeated measurements to capture changes in dietary habits in growing infants and young children over time prior to disease onset. The prospective design also reduced the effect of changes in dietary habits because parents were unaware of their child's autoantibody status at time food records were collected. Our analyses were also adjusted for known confounders for celiac disease (HLA, country, gender, and having a family member with celiac disease)[26]. Moreover, potential confounders such as socioeconomic status in terms of maternal smoking (during pregnancy), maternal education, and maternal age had previously already been analyzed and were not associated with risk of celiac disease[34] and therefore considered less likely to confound the results.

Limitations

This study has several limitations. First, the lack of information of analyzed gluten content in foods in national food composition databases. Therefore, the same conversion factor for estimation of gluten content in wheat, rye and barley was chosen because this method has been used in several previous studies[10,14,15,35]. Other studies have used cereal specific conversion factors for the estimation of gluten content[36]. Second, calculations of gluten content are approximate as they are based on self-reported dietary data. Different dietary assessment methods together with differences in methods of estimating gluten content are challenging when comparing results from previous studies. Conclusions should therefore be taken with care. A randomized trial of different amounts during early childhood in genetically at-risk individuals would therefore be warranted to confirm our findings.

Conclusions

Higher gluten intake in the first 5 years was associated with increased risk of celiac disease autoimmunity and celiac disease among genetically predisposed children.

References

1. Biesiekierski JR. What is gluten? Journal of Gastroenterology and Hepatology 2017;32 Suppl 1:78-81.
2. Lebwohl B, Sanders DS, Green PHR. Coeliac disease. Lancet 2018 6;391(10115):70-81.
3. Tjon JM, van Bergen J, Koning F. Celiac disease: how complicated can it get? Immunogenetics 2010;62:641-51.
4. Bouziat R, Hinterleitner R, Brown JJ, et al. Reovirus infection triggers inflammatory responses to dietary antigens and development of celiac disease. Science (New York, NY) 2017;356:44-50.
5. Kemppainen KM, Lynch KF, Liu E, et al. Factors That Increase Risk of Celiac Disease Autoimmunity After a Gastrointestinal Infection in Early Life. Clin Gastroenterol Hepatol 2017;15:694-702.e5.
6. Hagopian W, Lee HS, Liu E, et al. Co-occurrence of Type 1 Diabetes and Celiac Disease Autoimmunity. Pediatrics 2017 Nov;140 (5).
7. Agardh D, Lee HS, Kurppa K, et al. Clinical features of celiac disease: a prospective birth cohort. Pediatrics 2015;135:627-34.
8. Norris JM, Barriga K, Hoffenberg EJ, et al. Risk of celiac disease autoimmunity and timing of gluten introduction in the diet of infants at increased risk of disease. JAMA 2005;293 (19):2343-51.
9. Stordal K, White RA, Eggesbo M. Early feeding and risk of celiac disease in a prospective birth cohort. Pediatrics 2013;132:e1202-9.
10. Lionetti E, Castellaneta S, Francavilla R, et al. Introduction of gluten, HLA status, and the risk of celiac disease in children. The New England Journal of Medicine 2014;371:1295-303.

11. Vriezinga SL, Auricchio R, Bravi E, et al. Randomized feeding intervention in infants at high risk for celiac disease. The New England Journal of Medicine 2014;371:1304-15.
12. Szajewska H, Shamir R, Mearin L, et al. Gluten Introduction and the Risk of Coeliac Disease: A Position Paper by the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Journal of Pediatric Gastroenterology and Nutrition 2016;62:507-13.
13. Ivarsson A, Hernell O, Stenlund H, Persson LA. Breast-feeding protects against celiac disease. The American Journal of Clinical Nutrition 2002;75:914-21.
14. Crespo-Escobar P, Mearin ML, Hervas D, et al. The role of gluten consumption at an early age in celiac disease development: a further analysis of the prospective PreventCD cohort study. The American Journal of Clinical Nutrition 2017;105:890-6.
15. Andren Aronsson C, Lee HS, Koletzko S, et al. Effects of Gluten Intake on Risk of Celiac Disease: A Case-Control Study on a Swedish Birth Cohort. Clin Gastroenterol Hepatol 2016;14:403-9 e3.
16. Teddy Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY) study: study design. Pediatr Diabetes 2007;8:286-98.
17. Hagopian WA, Erlich H, Lernmark A, et al. The Environmental Determinants of Diabetes in the Young (TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants. Pediatr Diabetes 2011;12:733-43.
18. The Environmental Determinants of Diabetes in the Young (TEDDY) Study. Annals of the New York Academy of Sciences 2008;1150:1-13.
19. Vehik K, Fiske SW, Logan CA, et al. Methods, quality control and specimen management in an international multicentre investigation of type 1 diabetes: TEDDY. Diabetes Metab Res Rev 2013;29:557-67.

20. Rewers M, Hyoty H, Lernmark A, et al. The Environmental Determinants of Diabetes in the Young (TEDDY) Study: 2018 Update. Current diabetes reports 2018;18:136.
21. Yang J, Lynch KF, Uusitalo UM, et al. Factors associated with longitudinal food record compliance in a paediatric cohort study. Public Health Nutr 2016;19:804-13.
22. Joslowski G, Yang J, Aronsson CA, et al. Development of a harmonized food grouping system for between-country comparisons in the TEDDY Study. J Food Compost Anal 2017;63:79-88.
23. van Overbeek FM, Uil-Dieterman IG, Mol IW, Kohler-Brands L, Heymans HS, Mulder CJ. The daily gluten intake in relatives of patients with coeliac disease compared with that of the general Dutch population. European journal of gastroenterology & hepatology 1997;9:1097-9.
24. Bao F, Yu L, Babu S, et al. One third of HLA DQ2 homozygous patients with Type 1 diabetes express celiac disease-associated transglutaminase autoantobodies. J Autoimmun 1999;13(1):356-60.
25. Bingley PJ, Williams AJ, Norcross AJ, et al. Undiagnosed coeliac disease at age seven: population based prospective birth cohort study. BMJ (Clinical research ed) 2004;328:322-3.
26. Liu E, Lee HS, Aronsson CA, et al. Risk of pediatric celiac disease according to HLA haplotype and country. The New England journal of medicine 2014;371:42-9.
27. Willett WC, Howe GR, Kushi LH. Adjustment for total energy intake in epidemiologic studies. The American journal of clinical nutrition 1997;65:1220S-8S; discussion 9S-31S.
28. Asar O, Ritchie J, Kalra PA, Diggle PJ. Joint modelling of repeated measurement and time-to-event data: an introductory tutorial. International journal of epidemiology 2015;44:334-44.

29. Tsiatis A, Davidian M. Joint modeling of Longitudinal and Time-to-event data: an overview. Statistica Sinica 2004;14:809-34.
30. Zhang D, Chen MH, Ibrahim JG, Boye ME, Wang P, Shen W. Assessing model fit in joint models of longitudinal and survival data with applications to cancer clinical trials. Stat Med 2014;33(27):4715-33.
31. Zhang D, Chen MH, Ibrahim JG, Boye ME, Shen W. JMFit: A SAS Macro for Joint Models of Longitudinal and Survival Data. J Stat Softw. 2016 Jul;71(3).
32. Contal C, O´Quigley J. An application of changepoint methods in studying the effect of age on survival in breast cancer. Computional Statistics & Data Analysis 1999;30:253 - 70.
33. Lernmark B, Johnson SB, Vehik K, et al. Enrollment experiences in a pediatric longitudinal observational study: The Environmental Determinants of Diabetes in the Young (TEDDY) study. Contemp Clin Trials. 2011; 32(4):517-23.
34. Aronsson CA, Lee HS, Liu E, et al. Age at gluten introduction and risk of celiac disease. Pediatrics 2015 Feb; 135(2):239-45
35. Hopman EG, Pruijn R, Tabben EH, le Cessie S, Mearin ML. Food questionnaire for the assessment of gluten intake by children 1 to 4 years old. Journal of Pediatric Gastroenterology and Nutrition 2012;54:791-6.
36. Hoppe C, Trolle E, Gondolf UH, Husby S. Gluten intake in 6-36-month-old Danish infants and children based on a national survey. Journal of Nutritional Science 2013;2:e7.

494 **Table 1.** Descriptive characteristics of the study population, by study endpoint.

	Children always negative for tTG autoantibodies (n = 5,194)	Children with celiac disease autoimmunity (n = 1,216)	Children with celiac disease (n = 447)
Country	**n (%)**	**n (%)**	**n (%)**
USA	**2108 (40.5)**	**444 (36.5)**	**131 (29.3)**
- HLA DR3-DQ2/DR3-DQ2[a]	391 (18.5)	194 (43.7)	69 (52.7)
- HLA DR3-DQ2/DR4-DQ8[b]	849 (40.3)	183 (41.2)	50 (38.2)
- HLA others[c]	868 (41.2)	67 (15.1)	12 (9.1)
Finland	**1218 (23.5)**	**251 (20.6)**	**78 (17.4)**
- HLA DR3-DQ2/DR3-DQ2[a]	124 (10.2)	79 (31.5)	36 (46.2)
- HLA DR3-DQ2/DR4-DQ8[b]	376 (30.9)	120 (47.8)	30 (38.5)
- HLA others[c]	718 (58.9)	52 (20.7)	12 (15.4)
Germany	**314 (6.1)**	**57 (4.7)**	**16 (3.6)**
- HLA DR3-DQ2/DR3-DQ2[a]	50 (15.9)	22 (38.6)	9 (56.2)
- HLA DR3-DQ2/DR4-DQ8[b]	131 (41.7)	19 (33.3)	4 (25.0)
- HLA others[c]	133 (42.4)	16 (28.1)	3 (18.8)
Sweden	**1554 (29.9)**	**464 (38.2)**	**222 (49.7)**
- HLA DR3-DQ2/DR3-DQ2[a]	225 (14.5)	202 (43.5)	108 (48.6)
- HLA DR3-DQ2/DR4-DQ8[b]	690 (44.4)	152 (32.8)	66 (29.7)
- HLA others[c]	639 (41.1)	110 (23.7)	48 (21.6)
First degree relative with celiac disease			
Yes	129 (2.5)	126 (10.4)	77 (17.2)
No	5065 (97.5)	1090 (89.6)	370 (82.8)
Sex			
Female	2453 (47.3)	693 (57.0)	281 (62.9)
Male	2741 (52.7)	523 (43.0)	166 (37.1)
Breastfeeding duration, months, median (q1, q3)	7.8 (3.5, 12.0)	8.3 (5.0, 12.0)	8.1 (5.0, 12.0)
Age at gluten introduction, months, mean (SD)	6.2 (1.9)	6.1 (1.8)	5.9 (1.9)

Footnote: Detailed description of human leukocyte antigen (HLA) genotypes followed in TEDDY.

[a] DR3-DQA1*05:01-DQB1*02:01 / DR3-DQA1*05:01-DQB1*02:01

[b] DR4-DQA1*03:0X-DQB1*03:02 / DR3-DQA1*05:01-DQB1*02:01

[c] DR4-DQA1*03:0X-DQB1*03:02 / DR4-DQA1*03:0X-DQB1*03:02 or DR3-DQA1*05:01-DQB103:02 / DR8-DQA1*04:01-DQB1*04:02, DR4-DQA1*03-DQB1*03:02/DR3-DQA1*05:01-DQB1*02: 01, DR4-DQA1*03-DQB1*03:02/DR4-DQA1*03-DQB1*03: 02, DR4-DQA1*03-DQB1*03:02/DR8-DQA1*04:01-DQB1*04: 02, DR3-DQA1*05:01-DQB1*02:01/DR3-DQA1*05:01-DQB1*02:01, DR4-DQA1*03-DQB1*03:02/DR4-DQA1*03-DQB1*02, DR4-DQA1*03-DQB1*03:02/DR1-DQA1*01:01-DQB1*05:01, DR4-DQA1*03-DQB1*03:02/DR13-DQA1*01: 02-DQB1*06:04, DR4-DQA1*03-DQB1*03:02/DR9-DQA1*03-QB1*03:03,or DR3-DQA1*05:01-DQB1*02:01/DR9-DQA1*03-DQB1*03:03.

Table 2. Daily gluten intake and risk for developing celiac disease autoimmunity and celiac disease in the TEDDY study.

		Celiac disease autoimmunity		Celiac disease	
Analysis [a]	**Measurements of gluten**	**HR (95% CI)**	**p-value**	**HR (95% CI)**	**p-value**
Joint modeling, n=1,216	Absolute intake (g/day)	1.30 (1.22 to 1.38)	<0.001	1.50 (1.35 to 1.66)	<0.001
	Residual intake (g/day) [b]	1.40 (1.30 to 1.52)	<0.001	1.43 (1.23 to 1.68)	<0.001
	Intake/10kg body weight	1.87 (1.66 to 2.11)	<0.001	2.18 (1.75 to 2.71)	<0.001
Cox regression, n=1,216	Absolute intake (g/day)	1.14 (1.11 to 1.17)	<0.001	1.14 (1.09 to 1.20)	<0.001
	Residual intake (g/day) [b]	1.12 (1.09 to 1.15)	<0.001	1.07 (1.02 to 1.13)	0.011
	Intake/10kg body weight	1.19 (1.14 to 1.23)	<0.001	1.14 (1.07 to 1.22)	<0.001
Cox regression including only those with gluten consumption available within 1 year prior to time of event, n=905	Absolute intake (g/day)	1.12 (1.08 to 1.16)	<0.001	1.07 (1.02 to 1.13)	0.009
	Residual intake (g/day) [b]	1.09 (1.05 to 1.13)	<0.001	1.04 (0.99 to 1.10)	0.140
	Intake/10kg body weight	1.15 (1.10 to 1.20)	<0.001	1.12 (1.05 to 1.21)	0.002

[a] Adjusting for HLA-type, country, sex, FDR with celiac disease, and energy intake

[b] Age- and energy adjusted intake using the residual method (ref 27).

n = Number of children with celiac disease autoimmunity included in each analysis.

Table 3. Absolute risk for developing celiac disease autoimmunity and celiac disease in the TEDDY study, conditioned on HLA-type, country, sex, FDR with celiac disease, and energy intake. Cumulative hazard from the log-hazard model fit by the joint modeling in Table 2.

		Celiac disease autoimmunity			Celiac disease		
Measurements of gluten	**Gluten intake (Reference [a])**	**Absolute risk by 3 years of age if gluten was consumed at reference amount (%)**	**Absolute risk by 3 years of age if 1 unit higher than reference was consumed (%)**	**Absolute risk difference (%)**	**Absolute risk by 3 years of age if gluten was consumed at reference amount (%)**	**Absolute risk by 3 years of age if 1 unit higher than reference was consumed (%)**	**Absolute risk difference (%)**
Absolute intake (g/day)	3.71	28.1	34.2	6.1	20.7	27.9	7.2
Residual intake (g/day) [b]	0.48	18.7	24.6	5.9	7.8	10.7	2.9
Intake/10kg body weight	2.91	51.9	70.2	18.3	35.0	55.0	20.0

[a] Average gluten intake reported at the 2-year visit was considered as reference

[b] Age- and energy adjusted intake using the residual method (ref 27).

Abbreviation: FDR; First degree relative

Table 4. Daily absolute gluten intake reported at the 2-year visit and risk for developing celiac disease autoimmunity and celiac disease in the TEDDY study.

		Celiac disease autoimmunity		Celiac disease	
Model		**HR (95% CI)**	**p-value**	**HR (95% CI)**	**p-value**
A	≤ 2g/day	1		1	
	>2 g/day	1.49 (1.16 to 1.91)	0.002	1.75 (1.10 to 2.81)	0.019
B	≤ 2g/day	1		1	
	>2 g/day	1.62 (1.29 to 2.03)	<0.001	1.71 (1.12 to 2.60)	0.012

A: Adjusted for HLA-type, country, sex, FDR with celiac disease, and energy intake and the most recent gluten intake prior to the event as time dependent covariates

B: Adjusted for HLA-type, country, sex, FDR with celiac disease, and energy intake at 2 year TEDDY visit.

Table 5. Daily absolute gluten intake reported at the 2-year visit and risk for developing celiac disease autoimmunity and celiac disease in the TEDDY study.

	Celiac disease autoimmunity		Celiac disease	
Model[a]	**HR (95% CI)**	**p-value**	**HR (95% CI)**	**p-value**
≤ 2 g/day	1		1	
> 2 and ≤ 4 g/day	1.52 (1.20 to 1.93)	<0.001	1.57 (1.02 to 2.41)	0.041
> 4 and ≤ 6 g/day	1.77 (1.37 to 2.29)	<0.001	1.96 (1.24 to 3.11)	0.004
> 6 and ≤ 8 g/day	2.43 (1.76 to 3.36)	<0.001	2.69 (1.53 to 4.71)	<0.001
> 8 g/day	1.54 (0.81 to 2.93)	0.70	2.04 (0.68 to 6.08)	0.20

[a]Adjusted for HLA-type, country, sex, FDR with celiac disease, and energy intake at 2 year TEDDY visit

Acknowledgements

The TEDDY Study is funded by U01 DK63829, U01 DK63861, U01 DK63821, U01 DK63865, U01 DK63863, U01 DK63836, U01 DK63790, UC4 DK63829, UC4 DK63861, UC4 DK63821, UC4 DK63865, UC4 DK63863, UC4 DK63836, UC4 DK95300, UC4 DK100238, UC4 DK106955, UC4 DK112243, UC4 DK117483, and Contract No. HHSN267200700014C from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Child Health and Human Development (NICHD), National Institute of Environmental Health Sciences (NIEHS), Centers for Disease Control and Prevention (CDC), and JDRF. This work supported in part by the NIH/NCATS Clinical and Translational Science Awards to the University of Florida (UL1 TR000064) and the University of Colorado (UL1 TR001082).

Role of Funder Statement

The funders of this study were represented in The Environmental Determinants of Diabetes in the Young (TEDDY) Steering Committee. The funder had a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication. The corresponding author had the final say in submitting the manuscript for publication.

Access to Data and Data Analysis

Dr. Hye-Seung Lee had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Conflict of Interest Disclosures

No disclosures were reported.

Group Information - The TEDDY Study Group

Colorado Clinical Center: Marian Rewers, M.D., Ph.D., PI[1,4,5,6,10,11], Kimberly Bautista[12], Judith Baxter[9,12,15], Daniel Felipe-Morales, Kimberly Driscoll, Ph.D.[9], Brigitte I. Frohnert, M.D.[2,14], Marisa Gallant, M.D.[13], Patricia Gesualdo[2,6,12,14,15], Michelle Hoffman[12,13,14], Rachel Karban[12], Edwin Liu, M.D.[13], Jill Norris, Ph.D.[2,3,12], Andrea Steck, M.D.[3,14], Kathleen Waugh[6,7,12,15]. University of Colorado, Anschutz Medical Campus, Barbara Davis Center for Childhood Diabetes.

Finland Clinical Center: Jorma Toppari, M.D., Ph.D., PI[¥^1,4,11,14], Olli G. Simell, M.D., Ph.D., Annika Adamsson, Ph.D.[^12], Suvi Ahonen*[±§], Mari Åkerlund*[±§], Anne Hekkala, M.D.[µ¤], Henna Holappa[µ¤], Heikki Hyöty, M.D., Ph.D.*[±6], Anni Ikonen[µ¤], Jorma Ilonen, M.D., Ph.D.[¥¶3], Sinikka Jäminki*[±], Sanna Jokipuu[^12], Leena Karlsson[^], Miia Kähönen[µ¤12,14], Mikael Knip, M.D., Ph.D.*[±5], Minna-Liisa Koivikko[µ¤], Mirva Koreasalo*[±§2], Kalle Kurppa, M.D., Ph.D.*[±13], Jarita Kytölä*[±], Tiina Latva-aho[µ¤], Katri Lindfors, Ph.D.*[13], Maria Lönnrot, M.D., Ph.D.*[±6], Elina Mäntymäki[^], Markus Mattila*, Katja Multasuo[µ¤], Teija Mykkänen[µ¤], Tiina Niininen[±]*[12], Sari Niinistö[±§2], Mia Nyblom*[±], Sami Oikarinen, Ph.D.*[±], Paula Ollikainen[µ¤], Sirpa Pohjola[µ¤], Petra Rajala[^], Jenna Rautanen[±§], Anne Riikonen*[±§], Minna Romo[^], Suvi Ruohonen[^], Satu Simell, M.D., Ph.D.[¥13], Maija Sjöberg[¥^12], Aino Stenius[µ¤12], Päivi Tossavainen, M.D.[µ¤], Mari Vähä-Mäkilä[^], Sini Vainionpää[^12], Eeva Varjonen[¥^12], Riitta

Veijola, M.D., Ph.D.[µ¤14], Irene Viinikangas[µ¤], Suvi M. Virtanen, M.D., Ph.D.*[±§2]. [¥]University of Turku, *University of Tampere, [µ]University of Oulu, [^]Turku University Hospital, Hospital District of Southwest Finland, [±]Tampere University Hospital, [¤]Oulu University Hospital, §National Institute for Health and Welfare, Finland, [¶]University of Kuopio.

Georgia/Florida Clinical Center: Jin-Xiong She, Ph.D., PI[1,3,4,11], Desmond Schatz, M.D.*[4,5,7,8], Diane Hopkins[12], Leigh Steed[12,13,14,15], Jennifer Bryant[12], Katherine Silvis[2], Michael Haller, M.D.*[14], Melissa Gardiner[12], Richard McIndoe, Ph.D., Ashok Sharma, Stephen W. Anderson, M.D.[^], Laura Jacobsen, M.D.*[14], John Marks, DHSc.*[14], P.D. Towe*. Center for Biotechnology and Genomic Medicine, Augusta University. *University of Florida, [^]Pediatric Endocrine Associates, Atlanta.

Germany Clinical Center: Anette G. Ziegler, M.D., PI[1,3,4,11], Ezio Bonifacio Ph.D.*[5], Miryam D'Angelo, Anita Gavrisan, Cigdem Gezginci, Anja Heublein, Verena Hoffmann, Ph.D.[2], Sandra Hummel, Ph.D.[2], Andrea Keimer[¥2], Annette Knopff[7], Charlotte Koch, Sibylle Koletzko, M.D.[¶13], Claudia Ramminger[12], Roswith Roth, Ph.D.[9], Marlon Scholz, Joanna Stock[9,12,14], Katharina Warncke, M.D.[14], Lorena Wendel, Christiane Winkler, Ph.D.[2,12,15]. Forschergruppe Diabetes e.V. and Institute of Diabetes Research, Helmholtz Zentrum München, Forschergruppe Diabetes, and Klinikum rechts der Isar, Technische Universität München. *Center for Regenerative Therapies, TU Dresden, [¶]Dr. von Hauner Children's Hospital, Department of Gastroenterology, Ludwig Maximillians University Munich, [¥]University of Bonn, Department of Nutritional Epidemiology.

Sweden Clinical Center: Åke Lernmark, Ph.D., PI[1,3,4,5,6,8,10,11,15], Daniel Agardh, M.D., Ph.D.[6,13], Carin Andrén Aronsson, Ph.D.[2,12,13], Maria Ask, Jenny Bremer, Corrado Cilio, Ph.D., M.D.[5,6], Emelie Ericson-Hallström, Annika Fors, Lina Fransson, Thomas Gard, Rasmus Bennet, Monika Hansen, Hanna Jisser, Fredrik Johansen, Berglind Jonsdottir, M.D., Ph.D.[12], Silvija Jovic, Helena Elding Larsson, M.D., Ph.D.[6,14], Marielle Lindström, Markus Lundgren, M.D., Ph.D.[14], Maria Månsson-Martinez, Maria Markan, Jessica Melin[12], Zeliha Mestan, Caroline Nilsson, Karin Ottosson, Kobra Rahmati, Anita Ramelius, Falastin Salami, Anette Sjöberg, Birgitta Sjöberg, Carina Törn, Ph.D.[3,15], Anne Wallin, Åsa Wimar[14], Sofie Åberg. Lund University.

Washington Clinical Center: William A. Hagopian, M.D., Ph.D., PI[1,3,4,5,6,7,11,13,14], Michael Killian[6,7,12,13], Claire Cowen Crouch[12,14,15], Jennifer Skidmore[2], Ashley Akramoff, Masumeh Chavoshi, Kayleen Dunson, Rachel Hervey, Rachel Lyons, Arlene Meyer, Denise Mulenga[12], Jared Radtke, Matei Romancik, Davey Schmitt, Julie Schwabe, Sarah Zink. Pacific Northwest Research Institute.

Pennsylvania Satellite Center: Dorothy Becker, M.D., Margaret Franciscus, MaryEllen Dalmagro-Elias Smith[2], Ashi Daftary, M.D., Mary Beth Klein, Chrystal Yates. Children's Hospital of Pittsburgh of UPMC.

Data Coordinating Center: Jeffrey P. Krischer, Ph.D.,PI[1,4,5,10,11], Sarah Austin-Gonzalez, Maryouri Avendano, Sandra Baethke, Rasheedah Brown[12,15], Brant Burkhardt, Ph.D.[5,6], Martha Butterworth[2], Joanna Clasen, David Cuthbertson, Christopher Eberhard, Steven Fiske[9], Jennifer Garmeson, Veena Gowda, Kathleen Heyman, Belinda Hsiao, Christina Karges, Francisco Perez Laras, Hye-Seung Lee, Ph.D.[1,2,3,13,15], Qian Li[2,3], Shu Liu, Xiang Liu, Ph.D.[2,3], Kristian Lynch, Ph.D. [5,6,9,15], Colleen Maguire, Jamie Malloy, Cristina McCarthy[12,15],

Aubrie Merrell, Steven Meulemans, Hemang Parikh, Ph.D.[3], Ryan Quigley, Cassandra Remedios, Chris Shaffer, Laura Smith, Ph.D.[9,12], Susan Smith[12,15], Noah Sulman, Ph.D., Roy Tamura, Ph.D.[1,2,12,13,14], Dena Tewey, Michael Toth, Ulla Uusitalo, Ph.D.[2,15], Kendra Vehik, Ph.D.[4,5,6,9,14,15], Ponni Vijayakandipan, Keith Wood, Jimin Yang, Ph.D., R.D.[2,15]. *Past staff: Michael Abbondondolo, Lori Ballard, David Hadley, Ph.D., Wendy McLeod.* University of South Florida.

Autoantibody Reference Laboratories: Liping Yu, M.D.[^5], Dongmei Miao, M.D.[^], Polly Bingley, M.D., FRCP*[5], Alistair Williams*, Kyla Chandler*, Olivia Ball*, Ilana Kelland*, Sian Grace*, Ben Gillard*. [^]Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, *Bristol Medical School, University of Bristol UK.

HLA Reference Laboratory: William Hagopian[3], MD, PhD, Masumeh Chavoshi, Jared Radtke, Julie Schwabe. Pacific Northwest Research Institute, Seattle WA. (Previously Henry Erlich, Ph.D.[3], Steven J. Mack, Ph.D., Anna Lisa Fear. Center for Genetics, Children's Hospital Oakland Research Institute.)

Repository: Sandra Ke, Niveen Mulholland, Ph.D. NIDDK Biosample Repository at Fisher BioServices.

Project scientist: Beena Akolkar, Ph.D.[1,3,4,5,6,7,10,11]. National Institutes of Diabetes and Digestive and Kidney Diseases.

Other contributors: Kasia Bourcier, Ph.D.[5], National Institutes of Allergy and Infectious Diseases. Thomas Briese, Ph.D.[6,15], Columbia University. Suzanne Bennett Johnson, Ph.D.[9,12], Florida State University. Eric Triplett, Ph.D.[6], University of Florida.

Committees:[1]Ancillary Studies, [2]Diet, [3]Genetics, [4]Human Subjects/Publicity/Publications, [5]Immune Markers, [6]Infectious Agents, [7]Laboratory Implementation, [8]Maternal Studies, [9]Psychosocial, [10]Quality Assurance, [11]Steering, [12]Study Coordinators, [13]Celiac Disease, [14]Clinical Implementation, [15]Quality Assurance Subcommittee on Data Quality.